vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and Plymouth Industrial REIT, Inc. (PLYM). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $51.2M, roughly 1.5× Plymouth Industrial REIT, Inc.). Bioceres Crop Solutions Corp. runs the higher net margin — -9.6% vs -106.3%, a 96.7% gap on every dollar of revenue. On growth, Plymouth Industrial REIT, Inc. posted the faster year-over-year revenue change (-1.4% vs -16.8%). Over the past eight quarters, Plymouth Industrial REIT, Inc.'s revenue compounded faster (0.4% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Plymouth Industrial REIT, Inc. is a real estate investment trust focused on owning, operating, and acquiring high-quality industrial properties including distribution centers, warehouses, and light industrial facilities across key U.S. logistics hubs. It serves tenants in e-commerce, retail, manufacturing, and third-party logistics sectors, supporting diverse business supply chain needs.

BIOX vs PLYM — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.5× larger
BIOX
$77.6M
$51.2M
PLYM
Growing faster (revenue YoY)
PLYM
PLYM
+15.5% gap
PLYM
-1.4%
-16.8%
BIOX
Higher net margin
BIOX
BIOX
96.7% more per $
BIOX
-9.6%
-106.3%
PLYM
Faster 2-yr revenue CAGR
PLYM
PLYM
Annualised
PLYM
0.4%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
BIOX
BIOX
PLYM
PLYM
Revenue
$77.6M
$51.2M
Net Profit
$-7.4M
$-54.4M
Gross Margin
46.8%
Operating Margin
9.3%
-102.5%
Net Margin
-9.6%
-106.3%
Revenue YoY
-16.8%
-1.4%
Net Profit YoY
-20.2%
-248.5%
EPS (diluted)
$-0.12
$-1.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
PLYM
PLYM
Q3 25
$77.6M
$51.2M
Q2 25
$47.2M
Q1 25
$60.6M
$45.6M
Q4 24
$98.8M
$47.6M
Q3 24
$93.3M
$51.9M
Q2 24
$48.7M
Q1 24
$84.0M
$50.2M
Q4 23
$140.2M
$50.8M
Net Profit
BIOX
BIOX
PLYM
PLYM
Q3 25
$-7.4M
$-54.4M
Q2 25
$-6.1M
Q1 25
$-1.6M
$5.8M
Q4 24
$605.2K
$147.4M
Q3 24
$-6.2M
$-15.6M
Q2 24
$1.3M
Q1 24
$9.8M
$6.2M
Q4 23
$1.2M
$9.3M
Gross Margin
BIOX
BIOX
PLYM
PLYM
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Q1 24
50.8%
Q4 23
36.7%
Operating Margin
BIOX
BIOX
PLYM
PLYM
Q3 25
9.3%
-102.5%
Q2 25
-10.3%
Q1 25
1.5%
Q4 24
14.5%
Q3 24
2.5%
-29.6%
Q2 24
2.7%
Q1 24
15.7%
Q4 23
12.0%
Net Margin
BIOX
BIOX
PLYM
PLYM
Q3 25
-9.6%
-106.3%
Q2 25
-12.9%
Q1 25
-2.6%
12.8%
Q4 24
0.6%
309.9%
Q3 24
-6.6%
-30.1%
Q2 24
2.7%
Q1 24
11.6%
12.4%
Q4 23
0.9%
18.3%
EPS (diluted)
BIOX
BIOX
PLYM
PLYM
Q3 25
$-0.12
$-1.23
Q2 25
$-0.14
Q1 25
$-0.02
$0.13
Q4 24
$0.00
$3.24
Q3 24
$-0.10
$-0.35
Q2 24
$0.03
Q1 24
$0.14
$0.14
Q4 23
$0.00
$0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
PLYM
PLYM
Cash + ST InvestmentsLiquidity on hand
$15.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$470.1M
Total Assets
$734.9M
$1.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
PLYM
PLYM
Q3 25
$15.5M
Q2 25
Q1 25
$38.5M
Q4 24
$29.2M
Q3 24
$32.3M
Q2 24
Q1 24
$16.4M
Q4 23
$24.4M
Total Debt
BIOX
BIOX
PLYM
PLYM
Q3 25
Q2 25
Q1 25
Q4 24
$646.4M
Q3 24
Q2 24
Q1 24
Q4 23
$873.4M
Stockholders' Equity
BIOX
BIOX
PLYM
PLYM
Q3 25
$288.3M
$470.1M
Q2 25
$539.6M
Q1 25
$345.0M
$571.0M
Q4 24
$346.3M
$579.5M
Q3 24
$346.0M
$436.5M
Q2 24
$475.2M
Q1 24
$348.5M
$484.6M
Q4 23
$335.3M
$483.0M
Total Assets
BIOX
BIOX
PLYM
PLYM
Q3 25
$734.9M
$1.6B
Q2 25
$1.6B
Q1 25
$798.2M
$1.4B
Q4 24
$835.2M
$1.4B
Q3 24
$827.3M
$1.5B
Q2 24
$1.4B
Q1 24
$836.1M
$1.4B
Q4 23
$819.5M
$1.4B
Debt / Equity
BIOX
BIOX
PLYM
PLYM
Q3 25
Q2 25
Q1 25
Q4 24
1.12×
Q3 24
Q2 24
Q1 24
Q4 23
1.81×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
PLYM
PLYM
Operating Cash FlowLast quarter
$14.4M
$20.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
PLYM
PLYM
Q3 25
$14.4M
$20.0M
Q2 25
$23.4M
Q1 25
$23.3M
$15.6M
Q4 24
$-5.4M
$96.1M
Q3 24
$5.2M
$17.6M
Q2 24
$19.9M
Q1 24
$-17.4M
$16.6M
Q4 23
$21.1M
$18.6M
Cash Conversion
BIOX
BIOX
PLYM
PLYM
Q3 25
Q2 25
Q1 25
2.67×
Q4 24
-8.85×
0.65×
Q3 24
Q2 24
15.12×
Q1 24
-1.78×
2.67×
Q4 23
17.05×
2.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons